Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,475
Out of 4,479 analysts
6
Total ratings
n/a
Success rate
-35.57%
Average return
Main Sectors:
Top Industries:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $0.28 | +78.57% | 1 | May 7, 2024 | |
| CARA Cara Therapeutics | Reiterates: Buy | $18 | $0.28 | +6,377.15% | 1 | Jun 27, 2023 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $31.56 | -30.29% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $20.30 | +18.23% | 1 | Dec 19, 2022 | |
| ABUS Arbutus Biopharma | Upgrades: Buy | $4 → $5 | $3.13 | +59.74% | 1 | Feb 2, 2022 | |
| ROIV Roivant Sciences | Initiates: Buy | n/a | $10.56 | - | 1 | Oct 26, 2021 |
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $0.28
Upside: +78.57%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $18
Current: $0.28
Upside: +6,377.15%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $31.56
Upside: -30.29%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $20.30
Upside: +18.23%
Arbutus Biopharma
Feb 2, 2022
Upgrades: Buy
Price Target: $4 → $5
Current: $3.13
Upside: +59.74%
Roivant Sciences
Oct 26, 2021
Initiates: Buy
Price Target: n/a
Current: $10.56
Upside: -